Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.

Synthetic Biologics, Inc. (NYSE:SYN) was among the biggest advancers, as the stock reacted to its quarterly results. On the other hand, Nektar Therapeutics (NASDAQ:NKTR) came under pressure following negative results from a late-study of its investigational cancer drug in combination of Bristol-Myers Squibb Company's (NYSE:BMY) Opdivo.

Bristol-Myers Squib, meanwhile, received the Food and Drug Administration's approval for its Lag-3 antibody relatilimab, in combination with Opdivo, for the treatment of advanced melanoma.

Here are the key catalysts that could move the needle on biopharma stocks in the unfolding week:

Conferences

AD/PD 2022: International Conference On Alzheimer's And Parkinson's Diseases And Related Neurological Disorders: March 15-22, in Barcelona, Spain
KeyBanc's Virtual Healthcare Conference: March 22-23
Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics, or ACMG: March 22-26, in Nashville, Tennessee
American Academy of Dermatology, or AAD, Annual Meeting: March 25-29, in Boston, Massachusetts

PDUFA Dates

Zogenix, Inc.'s (NASDAQ:ZGNX) supplemental new drug application seeking approval for Fintepla as a treatment for seizures associated Lennox-Gastaut syndrome, has a PDUFA goal date of Friday, March 25.

Clinical Readouts/Presentations

ACMG Meeting Presentations

Applied Therapeutics, Inc. (NASDAQ:APLT): additional Phase 1/2 data for AT-007 in galactosemia (Wednesday)

AAD Meeting Presentations

Brickell Biotech, Inc. (NASDAQ:BBI): results from the U.S. Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis
InflaRx N.V. (NASDAQ:IFRX): final data from Phase 2a open-label study with vilobelimab in patients with pyoderma gangrenosum (Saturday)
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN): Data from the Phase 1b study for eblasakimab (ASLAN004) in atopic dermatitis
Cara Therapeutics, Inc. (NASDAQ:CARA): biomarker data from the KARE Phase 2 clinical trial evaluating oral Korsuva for the treatment of moderate-to-severe pruritus in atopic dermatitis patients (Saturday)

Related Link: Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

Earnings

The earnings list presented is not comprehensive. Click here to access Benzinga's earnings calendar for the complete schedule.

Monday

Tuesday

Thursday

Friday

POINT Biopharma Global Inc. (NASDAQ:PNT) (before the market open)

Related Link: Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates